8-K: Flora Growth Corp. Secures New Cannabis Supply Agreement with Northern Green Canada, Terminating Previous Deal

Flora Growth Corp. has entered into a new supply agreement with Northern Green Canada for medicinal cannabis products in the German market, replacing a previous agreement with a Curaleaf affiliate.

Summary

• Flora Growth Corp. has entered into a new supply agreement with Northern Green Canada, an affiliate of Curaleaf Holdings, Inc., for the supply of medicinal cannabis products.
• The agreement, effective October 31, 2024, will see Flora distribute these products in the German market.
• This new agreement replaces a previous supply agreement from February 18, 2020, between Terra Verde LDA (a Curaleaf affiliate) and ACA Mller ADAG Pharma Vertriebs GmbH (a Flora affiliate).
• The new agreement includes minimum purchase obligations for Flora and minimum supply obligations for Northern Green.
• All products supplied must be used for medicinal purposes only, and Flora cannot resell them for non-medical use without prior written consent from Northern Green.
• Northern Green can terminate the agreement without cause with 60 days' written notice.
• The previous agreement was terminated on October 28, 2024, through a deed of termination, settlement, and release.

Sentiment

Score: 7

Explanation: The document indicates a positive development with a new supply agreement, but the termination clause and limited nature of the agreement introduce some uncertainty. The sentiment is therefore moderately positive.

Positives

• Flora Growth Corp. has secured a new supply agreement, ensuring a continued supply of medicinal cannabis products for the German market.
• The new agreement replaces a previous one, potentially offering improved terms or conditions.
• The agreement includes minimum purchase and supply obligations, providing a degree of certainty for both parties.

Negatives

• Northern Green has the right to terminate the agreement without cause with 60 days' written notice, introducing a potential risk for Flora.
• Flora is restricted from reselling the products for non-medical use without prior written consent, limiting potential market reach.

Risks

• The agreement can be terminated by Northern Green without cause with 60 days' notice, creating uncertainty for Flora's supply chain.
• The agreement is a limited transaction and not a broader, ongoing commercial relationship with Curaleaf, which may limit future opportunities.
• The minimum purchase obligation for Flora is conditional on the products meeting German regulatory requirements and no import bans being imposed.
• The minimum supply obligation for Northern Green is conditional on Flora paying for products on time.

Future Outlook

The document outlines a new supply agreement for medicinal cannabis products, indicating a continued focus on the German market. The agreement includes minimum purchase and supply obligations, suggesting a planned level of activity for the coming period. The agreement is a limited transaction and not a broader, ongoing commercial relationship with Curaleaf.

Management Comments

• Curaleaf stated the new supply agreement was 'ready for signing' on October 28, 2024.

Industry Context

This announcement reflects the ongoing activity in the medicinal cannabis market, with companies establishing supply chains to meet demand in key markets like Germany. The involvement of Curaleaf, a major player in the cannabis industry, highlights the competitive landscape and the importance of securing reliable supply agreements.

Comparison to Industry Standards

• The agreement between Flora and Northern Green is similar to other supply agreements in the cannabis industry, which often include minimum purchase and supply obligations.
• The 60-day termination clause without cause is a common feature in such agreements, providing flexibility for suppliers.
• The requirement for medicinal use only and restrictions on resale are standard practices in the regulated cannabis market.
• The agreement is a limited transaction and not a broader, ongoing commercial relationship with Curaleaf, which is different from some other supply agreements that are part of larger strategic partnerships.

Stakeholder Impact

• Shareholders will likely view the new supply agreement positively, as it ensures a continued supply of products for the German market.
• Employees involved in distribution and sales will be impacted by the new agreement.
• Customers in the German market will benefit from the continued availability of medicinal cannabis products.
• Suppliers to Flora may be impacted by the shift in supply from the previous agreement.

Next Steps

• Flora will begin distributing medicinal cannabis products in the German market under the new agreement.
• Both parties will need to fulfill their minimum purchase and supply obligations.
• Flora will need to ensure compliance with the medicinal use restrictions and obtain prior written consent for any non-medical resales.
• Both parties will need to adhere to the terms of the agreement, including the 60-day termination clause.

Key Dates

Keywords

cannabis, medicinal cannabis, supply agreement, Flora Growth Corp, Northern Green Canada, Curaleaf, German market, distribution, termination, minimum purchase obligation, minimum supply obligation